Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report

Lisa K Moores, Tobias Tritschler, Shari Brosnahan, Marc Carrier, Jacob F Collen, Kevin Doerschug, Aaron B Holley, David Jimenez, Gregoire Le Gal, Parth Rali, Philip Wells, Lisa K Moores, Tobias Tritschler, Shari Brosnahan, Marc Carrier, Jacob F Collen, Kevin Doerschug, Aaron B Holley, David Jimenez, Gregoire Le Gal, Parth Rali, Philip Wells

Abstract

Background: Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE.

Methods: A group of approved panelists developed key clinical questions by using the PICO (Population, Intervention, Comparator, Outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis, and treatment of VTE in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase, and Cochrane Controlled Register of Trials were systematically searched for relevant literature, and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process.

Results: The systematic review and critical analysis of the literature based on 13 Population, Intervention, Comparator, Outcome questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements.

Conclusions: The evidence on the optimal strategies to prevent, diagnose, and treat VTE in patients with COVID-19 is sparse but rapidly evolving.

Keywords: COVID-19; DIC; DVT; VTE; hypercoagulability; pulmonary embolism.

Published by Elsevier Inc.

References

    1. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19 [published online ahead of print April 18, 2020]. Am J Emerg Med..
    1. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786–787.
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
    1. Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424.
    1. Helms J., Tacquard C., Severac F. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098.
    1. Klok F.A., Kruip M., van der Meer N.J.M. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
    1. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–150.
    1. Llitjos J.F., Leclerc M., Chochois C. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–1746.
    1. Lodigiani C., Iapichino G., Carenzo L. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
    1. Middeldorp S., Coppens M., van Haaps T.F. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.
    1. Poissy J., Goutay J., Caplan M. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142(2):184–186.
    1. Spiezia L., Boscolo A., Poletto F. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000.
    1. Thomas W., Varley J., Johnston A. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76–77.
    1. Xu J.F., Wang L., Zhao L. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients [published online ahead of print March 24, 2020] Preprints. 2020
    1. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study [published online ahead of print May 6, 2020]. Ann Intern Med..
    1. Escher R., Breakey N., Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.
    1. Coronavirus Disease 2019 (COVID-19) treatment guidelines.
    1. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.
    1. Kahn S.R., Lim W., Dunn A.S. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e195S–e226S.
    1. Kearon C., Akl E.A., Ornelas J. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352.
    1. Konstantinides S.V., Meyer G., Becattini C. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur Respir J. 2019;54(3)
    1. Schunemann H.J., Cushman M., Burnett A.E. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–3225.
    1. Iba T., Levy J.H., Warkentin T.E. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989–1994.
    1. Djulbegovic B, Guyatt G. Evidence vs consensus in clinical practice guidelines [published online ahead of print July 19, 2019]. JAMA..
    1. Ranucci M., Ballotta A., Di Dedda U. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751.
    1. Wang T., Chen R., Liu C. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362–e363.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
    1. Cohen A.T., Davidson B.L., Gallus A.S. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–329.
    1. Leizorovicz A., Cohen A.T., Turpie A.G. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–879.
    1. Samama M.M., Cohen A.T., Darmon J.Y. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800.
    1. Barbar S., Noventa F., Rossetto V. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457.
    1. Spyropoulos A.C., Anderson F.A., Jr., FitzGerald G. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
    1. Cobben M.R.R.N.B., Lijfering W.M., Cannegieter S.C. Validation of risk assessment models for venous thrombosis in hospitalized medical patients. Res Pract Thromb Haemost. 2019;3:217–225.
    1. Cohen A.T., Spiro T.E., Spyropoulos A.C. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014;12(4):479–487.
    1. Gibson C.M., Spyropoulos A.C., Cohen A.T. The IMPROVEDD VTE Risk Score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open. 2017;1(1):e56–e65.
    1. Greene M.T., Spyropoulos A.C., Chopra V. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med. 2016;129(9) 1001.e1009-1001.e1018.
    1. Mahan C.E., Liu Y., Turpie A.G. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR) Thromb Haemost. 2014;112(4):692–699.
    1. Moumneh T., Riou J., Douillet D. Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: a cohort study. J Thromb Haemost. 2020;18(6):1398-1407.
    1. Nendaz M., Spirk D., Kucher N. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE) Thromb Haemost. 2014;111(3):531–538.
    1. Rosenberg D., Eichorn A., Alarcon M., McCullagh L., McGinn T., Spyropoulos A.C. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3(6)
    1. Vardi M., Ghanem-Zoubi N.O., Zidan R., Yurin V., Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost. 2013;11(3):467–473.
    1. Darzi A.J., Karam S.G., Charide R. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020;135(20):1788-1810.
    1. Fraisse F., Holzapfel L., Couland J.M. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161(4 pt 1):1109–1114.
    1. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–1314.
    1. Shorr A.F., Williams M.D. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost. 2009;101(1):139–144.
    1. Alhazzani W., Lim W., Jaeschke R.Z., Murad M.H., Cade J., Cook D.J. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2088–2098.
    1. Kaplan D., Casper T.C., Elliott C.G. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148(5):1224–1230.
    1. Neumann I., Izcovich A., Zhang Y. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv. 2020;4(7):1512–1517.
    1. Collaborative overview of randomised trials of antiplatelet therapy—III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6923):235–246.
    1. Paranjpe I., Fuster V., Lala A. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124.
    1. Amin A.N., Varker H., Princic N., Lin J., Thompson S., Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231–238.
    1. Bajaj N.S., Vaduganathan M., Qamar A. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: a trial sequential and cumulative meta-analysis. PLoS Med. 2019;16(4)
    1. Spyropoulos A.C., Lipardi C., Xu J. Modified IMPROVE VTE Risk Score and Elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for Extended Thromboprophylaxis. TH Open. 2020;4(1):e59–e65.
    1. Spyropoulos A.C., Ageno W., Albers G.W. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118–1127.
    1. Arabi Y.M., Al-Hameed F., Burns K.E.A. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med. 2019;380(14):1305–1315.
    1. Marone E.M., Rinaldi L F. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations. J Vasc Surg Venous Lymphat Disord. 2020;8(4):694–695.
    1. Agnelli G., Buller H.R., Cohen A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
    1. Hokusai V.T.E.I., Buller H.R., Decousus H. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415.
    1. EINSTEIN–PE Investigators. Büller H.R., Prins M.H. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297.
    1. EINSTEIN Investigators. Bauersachs R., Berkowitz S.D. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
    1. Testa S., Prandoni P., Paoletti O. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents. The Cremona experience. J Thromb Haemost. 2020;18(6):1320-1323.
    1. Smythe M.A., Priziola J., Dobesh P.P., Wirth D., Cuker A., Wittkowsky A.K. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):165–186.
    1. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):188S–203S.
    1. Meyer G., Vicaut E., Konstantinides S.V. Fibrinolysis for intermediate-risk pulmonary embolism. N Engl J Med. 2014;371(6):581–582.
    1. Tian S., Xiong Y., Liu H. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007-1014.
    1. Luk C., Wells P.S., Anderson D., Kovacs M.J. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 2001;111(4):270–273.
    1. Carrier M., Le Gal G., Cho R., Tierney S., Rodger M., Lee A.Y. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760–765.
    1. Ihaddadene R., Le Gal G., Delluc A., Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014;134(1):93–95.
    1. Schulman S., Zondag M., Linkins L. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13(6):1010–1018.
    1. Clinical management of severe acute respiratory infection when COVID-19 is suspected.
    1. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions.
    1. Bikdeli B., Madhavan M.V., Jimenez D. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973.
    1. Casini A., Alberio L., Angelillo-Scherrer A. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19—a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly. 2020;150:w20247.
    1. Hunt B.R.A., McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.
    1. Marietta M., Ageno W., Artoni A. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) Blood Transfus. 2020;18(3):167-169.
    1. Oudkerk M, Büller HR, Kuijpers D, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands [published online ahead of print April 23, 2020]. Radiology..
    1. Thachil J., Tang N., Gando S. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
    1. Vivas D, Roldán V, Esteve-Pastor MA, et al. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology [article in Spanish] [published online ahead of print April 22, 2020]. Rev Esp Cardiol..
    1. Zhai Z., Li C., Chen Y. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. 2020;120(6):937-948.
    1. Barnes G.D., Burnett A., Allen A. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020;50(1):72–81.
    1. Zagury-Orly I., Schwartzstein R M. Covid-19—a reminder to reason. J Med. 2020;383(3):e12.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다